More than 150 listed companies disclosed the semi-annual report of the pharmaceutical industry on the stage to accelerate the development of the wind.

As of September, the half-yearly report of listed companies in 2020 will come to an end.
As of August 26, according to incomplete statistics from health Times reporters, more than 150 listed companies in the A-share biopharmaceutical industry have published half-yearly reports, of which 92 listed companies have achieved different degrees of increase in net profit attributable to shareholders of listed companies, accounting for more than 60%.
reporter combed the recent out of the pharmaceutical leading enterprises semi-annual report found that medical equipment, biopharmaceuticals, chemicals and other sectors are still rising faster.
Pointed out that the entire pharmaceutical industry chain is standing on the wind to accelerate the development of the wind.
Specifically, although the main factors driving the profit growth of listed companies are different, but it can be seen that, driven by the wind, the fundamentals of the entire pharmaceutical sector are improving, so that the capital market is expected to form a performance and valuation resonance, thus becoming the focus of capital group heating.
China Pharma's first-half net profit exceeded 700 million yuan, and on the evening of August 25th, China Pharma released its first half 2020 report, reporting revenue of RMB18,809 million, up 11.56% YoY;
annual report analysis of the first half of the operating situation, said that during the epidemic, the company's international trade sector to do a good job in the prevention of epidemic materials reserves and exports, achieved operating income of 7.244 billion yuan, up 84.02% YoY, operating profit of 863 million yuan, up 112.28% YoY.
addition, in the pharmaceutical business sector, the number of hospital outpatients during the outbreak significantly decreased, maintained the continued growth of sales revenue, the first half of the operating income of 12.169 billion yuan, an increase of 12.15 percent year-on-year.
, however, due to the decline in the proportion of hospital net sales and the extension of the account period, profit decreased, resulting in an operating profit of 319 million yuan, down 36.83 percent year-on-year.
Fosun Pharma's first-half net profit of 1.715 billion yuan: Nucleic acid testing kit contributed significantly on the same day, Shanghai Fosun Pharma released its 2020 half-year report, which showed that operating income in the first half of 2020 was RMB14.03 billion, down 1% YoY .02%; Net profit attributable to shareholders of listed companies was RMB1,715 million, up 13.1% YoY; net profit attributable to shareholders of listed companies, net of non-recurring profit and loss, was RMB1,304 million, up 11.71% YoY from the same period in 2019.
Regarding the main growth points, the semi-annual report said that, first, the new coronavirus nucleic acid testing kit, negative pressure ambulances and ventilators and other anti-epidemic products contributed more;
Despite the year-on-year decline in revenue, Fosun Pharma achieved revenue of 4,071 million yuan in countries other than Chinese mainland during the reporting period, accounting for 29.02% of total revenue, and rapid and steady internationalization.
, president and chief executive officer of Fosun Pharma, said the new crown outbreak has had a greater impact and uncertainty on the global and Chinese economy.
in the future to do a good job in the existing business and industrial upgrading on the basis of a firm innovation, internationalization, efficient operation, to ensure long-term growth in performance.
Fudan Zhangjiang's first-half revenue fell 40%, outpatient medication is still in the process of gradual recovery Compared with other recently disclosed growth, Fudan Zhangjiang semi-annual report shows that in January-June 2020, operating income reached 236 million yuan, down 39% YoY .69%; Net profit attributable to shareholders of listed companies was RMB29,078.9 million, down 68.30% YoY; net profit attributable to shareholders of listed companies, net of non-recurring gains and losses, was RMB10,530.6 million, down 86.25% YoY.
semi-annual report, as the current outbreak control period, hospitals and affiliated departments are still in the process of gradual recovery, the number of patients to the hospital and the frequency of visits is still significantly lower than normal levels.
affected by the overall patient care environment, the company's 2020 half-year operating results were significantly affected, with revenue declining during the reporting period.
For the entire biopharmaceutical industry, affected by the outbreak, performance became polarized, on the one hand, affected by the outbreak, hospital outpatients reduced, related performance was affected, relatively reduced revenue;
se.g. Jinyuan Medicine, new coronavirus nucleic acid detection revenue increased, resulting in operating income of RMB3.475 billion in the first half of 2020, up 36.63% YoY, and net profit attributable to shareholders of listed companies was RMB556 million, up 223% YoY .71 percent; Anglo Medical, which made protective clothing and disposable masks, reported a pre-profit of 1.9 billion yuan to 2.1 billion yuan in the first half of the year, up 2581.8% to 2864.1% year-on-year.
, the medical sector is on a fast-growing footing.
.